Cohort of Patients With Ulcerative Colitis or Polyps Followed in CHU de Bordeaux Associated With a Biocollection - COLIBRI
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Blood sample, biopsy.
- Who it may be relevant to
- Registry conditions: Ulcerative Colitis, Inflammatory Bowel Disease (IBD), Acute Severe Ulcerative Colitis. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Ulcerative colitis (UC) is a chronic disease characterized by acute episodes of bloody diarrhea with varying degrees of severity. The most feared event, acute severe UC, can lead to life-threatening and systemic complications. Little is known about the determinants of severity in UC. The investigators hypothesize that distinct severity phenotypes of UC arise from intricated host-microbiota mechanisms influencing repair mechanisms. Our first and main objective is to study the natural history of UC during a one-year time period in a cohort of patients.
Detailed description
Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by acute episodes of varying-severity bloody diarrhea. Acute severe colitis poses systemic risks. In our pilot ITAC project, the investigators found a direct link between deep colonic ulcers and systemic inflammation in acute severe colitis, suggesting repair failure. Conversely, excessive repair in UC can lead to colorectal neoplasia, especially sessile serrated adenomas in remission cases.. The investigators plan to prospectively collect tissue and blood samples of patients with UC or non-UC patients with polyps undergoing endoscopy in the Gastroenterology unit or colectomy in the Abdominal surgery unit of CHU de Bordeaux. For all patients, additional biopsies will be collected for histology, microbiota characterization, transcriptomic profiling and cells phenotyping. Additional blood samples will be collected for immune cells phenotyping, genetic profiling, and multiplex cytokines measurement. Routine clinical, endoscopic and biological data will be collected using the Entrepot de Données de Santé of CHU de Bordeaux. The patients will be divided in groups based on the endoscopy phenotype: unactive disease, non-severe active disease, severe disease and on the presence of polyps. Patients without ulcerative colitis with polyps will be studied as a control group.clinical, endoscopic and biological data will be collected using the Entrepot de Données de Santé of CHU de Bordeaux. The patients will be divided in groups based on the endoscopy phenotype: unactive disease, non-severe active disease, severe disease and on the presence of polyps. Patients without ulcerative colitis with polyps will be studied as a control group.
Interventions
- Other Blood sample
3 blood samples - Procedure biopsy
3 pairs of biopsy realised during the coloscopy
Primary outcome measures
- Mayo clinical activity score [Time frame: Baseline, Month 12]
- UCEIS endoscopic activity score [Time frame: Baseline, Month 12]
- Nancy histological activity score [Time frame: Baseline, Month 12]
- Advanced therapy (biologics or small molecules) [Time frame: Baseline, Month 12]
- Hospitalization due to disease flare [Time frame: Baseline, Month 12]
- Colectomy [Time frame: Baseline, Month 12]
Eligibility criteria
- Inclusion criteria:
- General Inclusion Criteria:
- Patients covered by a social security system.
- French-speaking patients.
- Patients aged ≥18 years.
- Patients who have provided free, informed, and written consent (no later than the inclusion day and before any research-related examination).
- Specific Inclusion Criteria for the UC Group:
- Patients diagnosed with ulcerative colitis (UC) according to the European Crohn's and Colitis Organisation (ECCO) guidelines.
- Patients undergoing lower gastrointestinal endoscopy or rectocolic surgery.
- Non-UC Patients with Polyps Group:
- Patients undergoing colonoscopy with resection of hyperplastic polyps in the rectum, sessile serrated lesions, or adenomas >2 cm.
- Exclusion criteria:
- Patients with perianal, ileal lesions, or endoscopic features of colonic lesions suggestive of Crohn's disease.
- Pregnant or breastfeeding women.
- Patients under legal protection or unable to provide informed consent.
- Patients deprived of liberty by judicial or administrative decision, hospitalized without consent, or admitted to a healthcare or social institution for reasons unrelated to the study.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Non-randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Other
Study locations
France · 1 center
- CHU de Bordeaux — Pessac
Identifiers
NCT: NCT07082231 · CHUBX 2024/61